Bempedoic acid and/or its fixed-dose combination with ezetimibe
Pre-clinicalActive 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypercholesterolemia
Conditions
Hypercholesterolemia, Mixed Dyslipidemia
Trial Timeline
Jan 15, 2021 → Oct 30, 2026
NCT ID
NCT04579367About Bempedoic acid and/or its fixed-dose combination with ezetimibe
Bempedoic acid and/or its fixed-dose combination with ezetimibe is a pre-clinical stage product being developed by Daiichi Sankyo for Hypercholesterolemia. The current trial status is active. This product is registered under clinical trial identifier NCT04579367. Target conditions include Hypercholesterolemia, Mixed Dyslipidemia.
What happened to similar drugs?
20 of 20 similar drugs in Hypercholesterolemia were approved
Approved (20) Terminated (2) Active (0)
✅generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
✅colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
✅colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
Hype Score Breakdown
Clinical
3
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04579367 | Pre-clinical | Active |
Competing Products
20 competing products in Hypercholesterolemia